Cited by 11Escherichia coli research studiesAntibiotic Resistance in BacteriaSalmonella and Campylobacter epidemiology

Distribution of extraintestinal pathogenic Escherichia coli O-serotypes and antibiotic resistance in blood isolates collected from patients in a surveillance study in Japan

Open access
Matsumoto, Tetsuya, Mikamo, Hiroshige, Ohge, Hiroki, Yanagihara, Katsunori, Weerdenburg, Eveline, Go, Oscar, Spiessens, Bart, van Geet, Gunter +7 more·2022·Journal of Infection and Chemotherapy

Abstract

Introduction Invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease (IED), characterised by sepsis and bacteraemia, is a major global healthcare concern worsened by emerging multidrug resistant (MDR) strains. The development of multivalent prophylactic vaccines targeting E. coli strains of IED-associated O-serotypes could address this. A better understanding of O-serotype distribution is required for this purpose. Here, we characterised O-serotype prevalence and drug resistance among ExPEC bacteraemia isolates in Japan.Methods E. coli blood isolates from patients aged ≥60 years with bacteraemia were obtained from a retrospective surveillance study in Japan (2015-2017). O-serotyping was performed by agglutination; for isolates non-typeable by agglutination, O-genotyping was performed. Antimicrobial susceptibility was evaluated by broth microdilution using a 21-antibiotic panel. The frequency of drug resistant (DR) isolates was evaluated by antimicrobial susceptibility testing.Results Of 401 ExPEC bacteraemia isolates evaluated, the most prevalent O-serotype (≥1%) was O25 (28.7% [n = 115]), followed by O1 (14.2% [n = 57]), O2 (8.5% n = 34]), O6 (5.5% [n = 22]), O75, O18, O13, O16, O15, O4, O46/O134, O86, O8 and O83 (each <5% prevalence). These 14 O-serotypes accounted for 81.5% of isolates collected. In total, 19% (n = 77) of isolates were DR ≥ 3, of which 59.7% were O25. Fluoroquinolone-resistance among all and O25 isolates was most prevalent (35.7% and 84.3%, respectively). Almost all (98%) isolates identified as O25 were of subtype O25B.Conclusions E. coli serotype O25B showed the highest prevalence and highest multidrug resistance among ExPEC bacteraemia isolates from patients ≥60 years in Japan. Our data may inform development of multivalent glycoconjugate vaccines to prevent IED.

Integrity signals

Registry

Crossref · 10.1016/j.jiac.2022.07.001

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The citation lists haven’t been fetched yet

References 33 · Cited by 11

Authors
Matsumoto, T., Mikamo, H., Ohge, H., Yanagihara, K., Weerdenburg, E., Go, O., Spiessens, B., van Geet, G., van den Hoven, T., Momose, A., Hagiwara, Y., Nakayama, Y., Poolman, J., Geurtsen, J., & Kaku, M.
Affiliations
  • Tokyo Medical University (JP)
  • Aichi Medical University (JP)
  • Hiroshima University Hospital (JP)
  • Nagasaki University (JP)
  • Janssen (Netherlands) (NL)
  • Janssen Research & Development (United States) (US)
  • Janssen (Belgium) (BE)
  • Janssen Pharmaceutical K.K. (Japan) (JP)
  • Tohoku Medical and Pharmaceutical University (JP)
Corresponding author
  • Matsumoto, Tetsuya
  • Mikamo, Hiroshige
  • Ohge, Hiroki
  • Yanagihara, Katsunori
  • Weerdenburg, Eveline
  • Go, Oscar
  • Spiessens, Bart
  • Momose, Atsushi
  • Hagiwara, Yosuke
  • Nakayama, Yoshikazu
  • Poolman, Jan
  • Geurtsen, Jeroen
  • Kaku, Mitsuo
Venue
Journal of Infection and Chemotherapy
Publisher
Elsevier BV
Published
2022-11
Volume
28
Issue
11
Pages
1445-1451
ISSN
1341-321X (ISSN-L)
OpenAlex
W4285679624
Cited by
11
References
33
Citations by year
2026: 2 · 2025: 3 · 2024: 4 · 2023: 2
FWCI
1.41
Type
journal article
Language
en
Open access
Locations
  • Journal of Infection and Chemotherapy (acceptedVersion)
  • PubMed (publishedVersion)
Funders
  • Johnson and Johnson
  • Janssen Pharmaceuticals
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Escherichia coli research studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Salmonella and Campylobacter epidemiology
Keywords
extraintestinal pathogenic Escherichia coli, bacteremia, O serotypes, serotype distribution, multidrug resistance, antimicrobial resistance, fluoroquinolone resistance, multivalent vaccine, older adults, Japan, sepsis, O1, O2, O6+
MeSH terms
Extraintestinal Pathogenic Escherichia coli, Anti-Infective Agents, Drug Resistance, Microbial, Escherichia coli, Escherichia coli Infections, Humans, Japan, Retrospective Studies, Serotyping, Vaccines, Bacteremia, Serogroup

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review